| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LRRC17 |
| Uniprot No | Q8N6Y2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-249aa |
| 氨基酸序列 | RKASPGSVRSRVNHGRAGGGRRGSNPVKRYAPGLPCDVYTYLHEKYLDCQERKLVYVLPGWPQDLLHMLLARNKIRTLKNNMFSKFKKLKSLDLQQNEISKIESEAFFGLNKLTTLLLQHNQIKVLTEEVFIYTPLLSYLRLYDNPWHCTCEIETLISMLQIPRNRNLGNYAKCESPQEQKNKKLRQIKSEQLCNEEEKEQLDPKPQVSGRPPVIKPEVDSTFCHNYVFPI |
| 预测分子量 | 42.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LRRC17重组蛋白的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**: *LRRC17 regulates osteoblast differentiation and bone formation via BMP/Smad signaling*
**作者**: Kim JH, Lee SY, Park SH
**摘要**: 本研究探讨了LRRC17重组蛋白在成骨细胞分化和骨形成中的作用。通过体外实验发现，LRRC17通过增强BMP/Smad信号通路促进成骨细胞分化，并上调成骨相关基因(如Runx2和Osterix)的表达。动物实验进一步证实LRRC17重组蛋白可改善骨质疏松模型小鼠的骨密度，提示其潜在的治疗应用价值。
---
2. **文献名称**: *LRRC17 as a novel biomarker for inflammatory diseases: Recombinant protein-based functional analysis*
**作者**: Chen L, Wang X, Zhang Y
**摘要**: 该研究通过表达并纯化LRRC17重组蛋白，揭示了其在炎症性疾病中的调控作用。实验表明，LRRC17重组蛋白能够抑制NF-κB信号通路，减少促炎因子(如TNF-α和IL-6)的释放。此外，在类风湿性关节炎患者的血清中检测到LRRC17水平显著降低，提示其可能作为炎症性疾病的潜在生物标志物。
---
3. **文献名称**: *Structural and functional characterization of recombinant LRRC17 protein in cancer progression*
**作者**: Tanaka K, Nakamura M, Fujiwara T
**摘要**: 本研究解析了LRRC17重组蛋白的结构特征，并探索其在癌症转移中的作用。实验发现，LRRC17重组蛋白通过与整合素β1相互作用，抑制肿瘤细胞的迁移和侵袭能力。进一步的机制研究表明，LRRC17通过下调MMP-9的表达抑制细胞外基质降解，为开发靶向LRRC17的癌症治疗策略提供了依据。
---
**备注**：上述文献信息为示例性内容，实际研究中建议通过PubMed、Web of Science等数据库检索最新文献。若需具体文献的全文或DOI，可进一步补充关键词或年份范围。
LRRC17 (leucine-rich repeat-containing protein 17) is a member of the leucine-rich repeat (LRR) superfamily, characterized by tandem repeats of 20-30 amino acid motifs rich in leucine residues. These proteins are involved in diverse cellular processes, including protein-protein interactions, signal transduction, and extracellular matrix organization. LRRC17 is encoded by the *LRRC17* gene located on human chromosome 7q31.1 and is predominantly expressed in tissues such as bone, cartilage, and immune cells. Its structure features an N-terminal LRR domain, which mediates ligand recognition, and a C-terminal domain that may facilitate homotypic interactions or membrane association.
Functionally, LRRC17 has been implicated in osteoblast differentiation, cancer progression, and immune regulation. Studies suggest it interacts with TGF-β and NF-κB signaling pathways, modulating cell proliferation, adhesion, and inflammatory responses. In bone biology, LRRC17 may act as a negative regulator of osteogenesis, influencing bone mineral density and osteoporosis risk. In cancer, elevated LRRC17 expression correlates with tumor metastasis and poor prognosis, potentially by promoting epithelial-mesenchymal transition (EMT) or extracellular matrix remodeling.
Recombinant LRRC17 protein, produced via expression systems like *E. coli* or mammalian cells, enables functional studies and therapeutic exploration. Its purified form is used to investigate binding partners, signaling mechanisms, and cellular responses. Researchers also employ it in drug screening assays to identify inhibitors targeting LRRC17-associated pathologies. Despite progress, its precise molecular mechanisms and tissue-specific roles remain under investigation, highlighting the need for further structural and functional analyses to unlock its diagnostic or therapeutic potential.
×
